230 related articles for article (PubMed ID: 2145026)
1. P388 leukaemia cells resistant to the anthracycline menogaril lack multidrug resistant phenotype.
Badiner GJ; Moy BC; Smith KS; Tarpley WG; Groppi VE; Bhuyan BK
Br J Cancer; 1990 Sep; 62(3):378-84. PubMed ID: 2145026
[TBL] [Abstract][Full Text] [Related]
2. Cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to doxorubicin.
Chandrasekaran B; Dimling J; Capizzi RL
Cancer Treat Rep; 1987 Feb; 71(2):195-6. PubMed ID: 2948640
[TBL] [Abstract][Full Text] [Related]
3. Role of oxygen free radical formation in the mechanism of menogaril resistance in multidrug resistant tumor cells.
Sinha BK; Atwell J; Politi PM
Chem Biol Interact; 1990; 76(1):89-99. PubMed ID: 2168296
[TBL] [Abstract][Full Text] [Related]
4. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Schmidt H; Seshadri R; Israel M
Biochem Biophys Res Commun; 1985 Sep; 131(2):912-9. PubMed ID: 2932108
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey.
Adams WJ; McGovren JP; Dalm EA; Brewer JE; Hosley JD
Cancer Res; 1989 Nov; 49(22):6328-36. PubMed ID: 2529962
[TBL] [Abstract][Full Text] [Related]
7. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
[TBL] [Abstract][Full Text] [Related]
8. Menogaril, an anthracycline compound with a novel mechanism of action: cellular pharmacology.
Wierzba K; Sugimoto Y; Matsuo K; Toko T; Takeda S; Yamada Y; Tsukagoshi S
Jpn J Cancer Res; 1990 Aug; 81(8):842-9. PubMed ID: 2144516
[TBL] [Abstract][Full Text] [Related]
9. Activity of the anthracycline agent, 7-con-O-methylnogarol (7-OMEN), administered orally to mice bearing P388 or L1210 leukemia.
McGovren JP
Cancer Treat Rep; 1980; 64(4-5):727-9. PubMed ID: 6448690
[TBL] [Abstract][Full Text] [Related]
10. Reversal of drug sensitivity in MDR subline of P388 leukemia by gene-targeted antisense oligonucleotide.
Nakashima E; Matsushita R; Negishi H; Nomura M; Harada S; Yamamoto H; Miyamoto K; Ichimura F
J Pharm Sci; 1995 Oct; 84(10):1205-9. PubMed ID: 8801335
[TBL] [Abstract][Full Text] [Related]
11. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Goldenberg GJ; Wang H; Blair GW
Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
Yang JM; Goldenberg S; Gottesman MM; Hait WN
Cancer Res; 1994 Feb; 54(3):730-7. PubMed ID: 7905786
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of vincristine- and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin.
Tsuruo T; Iida H; Yamashiro M; Tsukagoshi S; Sakurai Y
Biochem Pharmacol; 1982 Oct; 31(19):3138-40. PubMed ID: 7150340
[TBL] [Abstract][Full Text] [Related]
14. Enhanced efflux of actinomycin D, vincristine, and vinblastine in adriamycin-resistant subline of P388 leukemia.
Inaba M; Sakurai Y
Cancer Lett; 1979 Dec; 8(2):111-5. PubMed ID: 555868
[TBL] [Abstract][Full Text] [Related]
15. Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity.
Fichtner I; Stein U; Hoffmann J; Winterfeld G; Pfeil D; Hentschel M
Anticancer Res; 1994; 14(5A):1995-2003. PubMed ID: 7847840
[TBL] [Abstract][Full Text] [Related]
16. V79 Chinese hamster lung cells resistant to the bis-alkylator bizelesin are multidrug-resistant.
Butryn RK; Smith KS; Adams EG; Abraham I; Stackpole J; Sampson KE; Bhuyan BK
Cancer Chemother Pharmacol; 1994; 34(1):44-50. PubMed ID: 7513620
[TBL] [Abstract][Full Text] [Related]
17. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin.
Mirski SE; Gerlach JH; Cole SP
Cancer Res; 1987 May; 47(10):2594-8. PubMed ID: 2436751
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of pirarubicin cytotoxicity by dipyridamole in doxorubicin-resistant mouse P388 leukemia cells.
Furusawa S; Fujimura T; Kawauchi H; Sasaki K; Takayanagi Y
Res Commun Chem Pathol Pharmacol; 1991 Mar; 71(3):321-36. PubMed ID: 2047575
[TBL] [Abstract][Full Text] [Related]
19. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.
Boesch D; Gavériaux C; Jachez B; Pourtier-Manzanedo A; Bollinger P; Loor F
Cancer Res; 1991 Aug; 51(16):4226-33. PubMed ID: 1678313
[TBL] [Abstract][Full Text] [Related]
20. Reversal of multidrug resistance by a novel quinoline derivative, MS-209.
Sato W; Fukazawa N; Nakanishi O; Baba M; Suzuki T; Yano O; Naito M; Tsuruo T
Cancer Chemother Pharmacol; 1995; 35(4):271-7. PubMed ID: 7828268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
